GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generex Biotechnology Corp (OTCPK:GNBTQ) » Definitions » PE Ratio (TTM)

Generex Biotechnology (Generex Biotechnology) PE Ratio (TTM) : At Loss (As of May. 11, 2024)


View and export this data going back to 1998. Start your Free Trial

What is Generex Biotechnology PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-11), Generex Biotechnology's share price is $0.0002. Generex Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52. Therefore, Generex Biotechnology's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Generex Biotechnology's PE Ratio (TTM) or its related term are showing as below:

GNBTQ' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



GNBTQ's PE Ratio (TTM) is not ranked
in the Biotechnology industry.
Industry Median: 28.5 vs GNBTQ: At Loss

Generex Biotechnology's Earnings per Share (Diluted) for the three months ended in Apr. 2021 was $-0.04. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52.

As of today (2024-05-11), Generex Biotechnology's share price is $0.0002. Generex Biotechnology's EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52. Therefore, Generex Biotechnology's PE Ratio without NRI for today is At Loss.

Generex Biotechnology's EPS without NRI for the three months ended in Apr. 2021 was $-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.52.

Generex Biotechnology's EPS (Basic) for the three months ended in Apr. 2021 was $0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Apr. 2021 was $-0.40.


Generex Biotechnology PE Ratio (TTM) Historical Data

The historical data trend for Generex Biotechnology's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generex Biotechnology PE Ratio (TTM) Chart

Generex Biotechnology Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss 0.15 At Loss At Loss

Generex Biotechnology Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Generex Biotechnology's PE Ratio (TTM)

For the Biotechnology subindustry, Generex Biotechnology's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generex Biotechnology's PE Ratio (TTM) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generex Biotechnology's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Generex Biotechnology's PE Ratio (TTM) falls into.



Generex Biotechnology PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Generex Biotechnology's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.0002/-0.520
=At Loss

Generex Biotechnology's Share Price of today is $0.0002.
Generex Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.52.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Generex Biotechnology  (OTCPK:GNBTQ) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Generex Biotechnology PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Generex Biotechnology's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Generex Biotechnology (Generex Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10102 USA Today Way, Miramar, FL, USA, 33025
Generex Biotechnology Corp is a Biotechnology company which is primarily engaged in the research and development of drug delivery systems and technologies. It mainly focuses on developing technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The company operates in the single segment being the Research and development of drug delivery systems and technologies for metabolic and immunological diseases. In addition, the company engages in developing proprietary vaccine formulations through its subsidiaries that work by stimulating the immune system to either attack offending agents that is cancer cells, bacteria, and viruses or to stop attacking benign elements.
Executives
Prioletti Mark Joseph Se director 1121 PALMER COURT CRYSTAL LAKE IL 60014
Salvo Lawrence Anthony Sr director 450 ALTON ROAD APT 3704 MIAMI BEACH FL 33139
Harold Gray Haines other: Consultant 11511 SW 127TH ST MIAMI FL 33176
Mark Fletcher officer: EVP General Counsel &Secretary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Brian Mcgee director 201 BRIDGELAND AVE TORONTO ONTARIO CANDA M6A 1Y7 A6 00000
Anderson James H Jr. director 33 HARBOUR SQUARE TORONTO A6 M5J2G2
Mark Corrao officer: CFO & Treasurer 531 AIRPORT NORTH OFFICE PARK, FORT WAYNE IN 46825
Purcell Richard David Jr. director, officer: SVP of Research & Drug Develop 65 FAIR HAVEN ROAD, FAIR HAVEN NJ 07704
Gary Herbert Lyman director 10102 USA TODAY WAY MIRAMAR FL 33025
Kevin Centofanti director 10102 USA TODAY WAY MIRAMAR FL 33025
Andrew Ro director, officer: SVP & Chief Investment Officer 10102 USA TODAY WAY MIRAMAR FL 33025
David Brusegard officer: Chief Operating Officer 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
Stephen Fellows officer: Chief Financial Officer 33 HARBOUR SQUARE SUITE 202 TORONTO A6 M5J 2G2
Hofe Eric Von director, officer: President of Subsidiary 4145 NORTH SERVICE ROAD, SUITE 200 BURLINGTON A6 L7L6A3
John P Barratt director 555 RICHMOND ST. W, SUITE 604 TORONTO A6 M5V3B1

Generex Biotechnology (Generex Biotechnology) Headlines

From GuruFocus